Table 2.
Characteristics of study subjects in Model 1 (APRI or Fib4) and Model 2 (combined APRI and Fib4 scores).
| nAHF | No nAHF | |
|---|---|---|
| Model 1 | ||
| APRI | ||
| Gender (n, male, female) | 12, 6 | 78, 38 |
| Age (years) | 48 ± 4 | 44 ± 1 |
| Ferritin (µg/L) | 1118 ± 191 | 625 ± 37*** |
| Transferrin saturation (%) | 74 ± 4 | 65 ± 2 |
| ALT (U/L) | 73 ± 11 | 29 ± 1*** |
| AST (U/L) | 46 ± 5 | 23 ± 0.7*** |
| Hepascore | 0.35 ± 0.06 | 0.21 ± 0.01** |
| TE (kPa) | 5.9 ± 0.9 | 4.9 ± 0.13 |
| Fib4 | ||
| Gender (n, male, female) | 27, 13 | 64, 30 |
| Age (years) | 57 ± 1.6 | 39 ± 1*** |
| Ferritin (µg/L) | 875 ± 114 | 613 ± 35* |
| Transferrin saturation (%) | 67 ± 3 | 65 ± 2 |
| ALT (U/L) | 37 ± 3 | 34 ± 3 |
| AST (U/L) | 31 ± 1 | 25 ± 1* |
| Hepascore | 0.27 ± 0.04 | 0.22 ± 0.01 |
| TE (kPa) | 5.4 ± 0.4 | 4.9 ± 0.1 |
| Model 2 | ||
| Gender (n, male, female) | 8, 5 | 60, 29 |
| Age (years) | 56 ± 3 | 40 ± 1*** |
| Ferritin (µg/L) | 1188 ± 250 | 595 ± 34*** |
| Transferrin saturation (%) | 74 ± 4 | 65 ± 2 |
| ALT (U/L) | 54 ± 6 | 29 ± 1*** |
| AST (U/L) | 38 ± 3 | 22 ± 1*** |
| Hepascore | 0.17 ± 0.11 | 0.05 ± 0.02 |
| TE (kPa) | 6.0 ± 1.1 | 4.9 ± 0.1 |
All data are presented as the mean ± SE.
ALT: alanine aminotransferase; APRI: aspartate aminotransferase to platelet ratio index; AST: aspartate aminotransferase; Fib4: fibrosis-4; GGT: gamma-glutamyl transferase; nAHF: noninvasive biomarker advanced hepatic fibrosis; No nAHF: no noninvasive biomarker advanced hepatic fibrosis; TE: transient elastography.
*P < 0.05, **P < 0.01, ***P < 0.0001 compared with nAHF group (unpaired t test).